762 related articles for article (PubMed ID: 25773866)
1. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
2. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
3. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
4. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
5. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
6. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
7. KIF5B-RET fusions in lung adenocarcinoma.
Kohno T; Ichikawa H; Totoki Y; Yasuda K; Hiramoto M; Nammo T; Sakamoto H; Tsuta K; Furuta K; Shimada Y; Iwakawa R; Ogiwara H; Oike T; Enari M; Schetter AJ; Okayama H; Haugen A; Skaug V; Chiku S; Yamanaka I; Arai Y; Watanabe S; Sekine I; Ogawa S; Harris CC; Tsuda H; Yoshida T; Yokota J; Shibata T
Nat Med; 2012 Feb; 18(3):375-7. PubMed ID: 22327624
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
9. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
10. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.
Zheng D; Wang R; Zhang Y; Pan Y; Cheng X; Cheng C; Zheng S; Li H; Gong R; Li Y; Shen X; Sun Y; Chen H
J Cancer Res Clin Oncol; 2016 Apr; 142(4):833-43. PubMed ID: 26646246
[TBL] [Abstract][Full Text] [Related]
12. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
13. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
14. RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
16. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
[TBL] [Abstract][Full Text] [Related]
18. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
[TBL] [Abstract][Full Text] [Related]
20. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Wang R; Hu H; Pan Y; Li Y; Ye T; Li C; Luo X; Wang L; Li H; Zhang Y; Li F; Lu Y; Lu Q; Xu J; Garfield D; Shen L; Ji H; Pao W; Sun Y; Chen H
J Clin Oncol; 2012 Dec; 30(35):4352-9. PubMed ID: 23150706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
